Comparative Immunogenicity Study of Two Hepatitis A Vaccines
Comparative Immunogenicity Study of Two Live Attenuated Hepatitis A Vaccines
Sponsor: China National Biotec Group Company Limited
Listed as NCT03231605, this PHASE4 trial focuses on Hepatitis A and remains ongoing. Sponsored by China National Biotec Group Company Limited, it has been updated 7 times since 2017, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Jan 2021 — Oct 2021 [monthly]
Unknown Status PHASE4
-
Aug 2019 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Enrolling By Invitation → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Aug 2019 [monthly]
Enrolling By Invitation PHASE4
-
Aug 2017 — Jun 2018 [monthly]
Enrolling By Invitation PHASE4
First recorded
Jul 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- China National Biotec Group Company Limited
- Shaanxi Provincial Center for Disease Control and Prevention
For direct contact, visit the study record on ClinicalTrials.gov .